title: [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)].
abstract: Lymph node metastases are rarely detected during radical prostatectomy (55/647 patients in our series or 8.5%) and several authors consider that lymphadenectomy is unnecessary in most cases. Criteria based on clinical stage, PSA and tumor grade have been elaborated in order to avoid pelvic lymph node dissection in a low risk population. It is commonly admitted that patients with clinically localized prostate cancer, a PSA level < 10 ng/ml, and a Gleason score < 7 could be spared a pelvic lymphadenectomy. In our series, these patients account for 12% of positive nodes. The best treatment for prostate cancer patients with a nodal disease is controversial. We compare the evolution of two groups of patients: radical prostatectomy alone or combined with an immediate adjuvant hormonal treatment. We observe a difference between the two groups for biological progression (PSA failure) but not yet for clinical progression nor for survival as our mean follow-up in only 6 years.
authors.affiliation: Service d'Urologie Cliniques Universitaires Saint-Luc, Bruxelles.
authors.forename: A
authors.initials: A
authors.lastname: Feyaerts
authors.forename: L
authors.initials: L
authors.lastname: Stainier
authors.forename: M C
authors.initials: MC
authors.lastname: Nollevaux
authors.forename: P
authors.initials: P
authors.lastname: De Groote
authors.forename: F
authors.initials: F
authors.lastname: Lorge
authors.forename: R
authors.initials: R
authors.lastname: Opsomer
authors.forename: F X
authors.initials: FX
authors.lastname: Wese
authors.forename: J P
authors.initials: JP
authors.lastname: Cosyns
authors.forename: P
authors.initials: P
authors.lastname: Van Cangh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen
vernacular_title: Prostatectomie radicale totale et ganglions positifs (stades pT1 à 4, N1 à 3, M0, D1).